// App-Quantinova.ai

: Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Researchers

Presenter

  • Kiran Naqvi

Principal Investigators

  • Koji Sasaki

  • Guillermo Montalban-Bravo

  • Michael S Teach

  • Sherry A. Pierce

  • Hagop M. Kantarjian

  • Guillermo Garcia-Manero

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Leukemia, University of Texas, Houston

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Myeloid neoplasms

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Splicing Factor 3b Subunit 1

  • Thrombocytosis

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved